What actually happens when a multinational has validated technology that isn't moving? The science works. The patents are clean. The market is real. And yet the technology stays parked.
In this episode of INNVENTURING, host Chad Arnold sits down with Colin Scott, Head of New Company Development at Innventure, to pull back the curtain on exactly how Innventure finds, evaluates, and builds transformative companies. Less than 2% of the opportunities that come through the door ever become an Innventure operating company.
Colin walks through the foundational philosophy behind Innventure's model, needs lead, technology follows, and breaks down the four-stage DownSelect process that separates the glitter from the gold. From the initial opportunity screen to the formation of a new company on day zero, this is the playbook that produced Accelsius, AeroFlexx, and Refinity.
He also unpacks the structural obstacles that keep validated technology stalled inside large organizations: budget cycles, misaligned time horizons, competing priorities, and the quiet cost of the people who eventually stop waiting. The fix is never technical. It's structural.
If you're a C-suite executive at a multinational sitting on technology you've validated but haven't commercialized, this episode was made for you.
A Companion to the Innventuring Podcast
The Crown Jewel Test
Ten questions to ask before you decide your technology is too valuable to move.
Most multinationals are sitting on validated technology that isn't moving. The science works. The patents are clean. The market is real. And the technology stays parked.
The reason is almost never the technology. It's everything around it. The internal math, the competing priorities, the time horizons, the people who eventually stop waiting. Every one of these is a structural problem, not a technical one. Which means the fix is structural too.
Run your stalled program through it. Be honest with the answers. The cost of inaction doesn't show up on any line item, so you have to go looking for it.
How This Works
Each question describes a reason validated technology stalls inside a company. Check the box on the left when the statement is true for your program. The right side shows how Innventure solves that issue. The more boxes you check, the stronger the case is for partnering.
The Ten Questions
Mostly checked boxes.
The program isn't failing on merit. It's failing on fit. Every box you checked is a structural obstacle, and structure is the one thing you can change without touching the technology. That is the situation Innventure is built for. We create and operate a real company around technology a multinational has already validated but chosen not to commercialize itself. New CEO, new team, its own P&L, its own clock. You stay close and keep meaningful upside. The science doesn't change. Everything around it does.
Mostly unchecked boxes.
Keep it inside. You have the customer, the timeline, the board appetite, and the team. The program isn't stuck. It's on the right path, and the right path is the one you're already on.
Honest answer: you weren't sure.
That's the most useful result of all. It usually means no one owns the outcome. Naming that is the first move, and it's the conversation we have every day.
